My watch list  

Basilea Pharmaceutica

Basilea Pharmaceutica AG
Public (SWX: [1])
HeadquartersBasel, Switzerland
Key peopleAnthony Man (CEO)

Basilea Pharmaceutica Ltd. is a Switzerland-based biopharmaceutical company that was formed as a spin-off entity from the drug giant Hoffmann–La Roche in October 2000. Basilea is engaged in the development of antibacterial and antifungal agents to combat drug resistance.

The company is based in Basel, Switzerland. It has subsidiaries in France (Basilea Pharmaceuticals SAS), Germany (Basilea Pharmaceuticals GmbH), Denmark (Basilea Pharmaceuticals A/S), the People's Republic of China (Basilea Pharmaceutica China Ltd), Spain (Basilea Pharmaceuticals Iberia SL), the United Kingdom (Basilea Pharmaceuticals Ltd.), and the United States of America (Basilea Pharmaceuticals Inc.)[1]. According to stock filings, it had 196 employees as of June 2007[2].

Basilea currently has no drugs being marketed. It has three investigational drugs in phase III clinical development: ceftobiprole, a cephalosporin antibiotic with activity against methicillin-resistant Staphylococcus aureus (being developed in cooperation with Johnson & Johnson), isavuconazole, a broad-spectrum triazole antifungal drug, and alitretinoin, an oral retinoid for the treatment of Chronic Hand Eczema.[3]

  1. ^
  2. ^
  3. ^
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Basilea_Pharmaceutica". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE